Publication

Intermediate Dose Low-Molecular-Weight Heparin for Thrombosis Prophylaxis: Systematic Review with Meta-Analysis and Trial Sequential Analysis

Eck, R. J., Bult, W., Wetterslev, J., Gans, R. O. B., Meijer, K., Keus, F. & van der Horst, I. C. C., Nov-2019, In : Seminars in thrombosis and hemostasis. 45, 8, p. 810-824 15 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Intermediate Dose Low-Molecular-Weight Heparin for

    Final publisher's version, 681 KB, PDF document

    Request copy

  • Intermediate dose low-molecular-weight heparin for thrombosis prophylaxis systematic review with meta-analysis and trial

    Final publisher's version, 285 KB, PDF document

    Embargo ends: 17/10/2020

    Request copy

DOI

Different doses of low-molecular-weight heparin (LMWH) are registered and used for thrombosis prophylaxis. We assessed benefits and harms of thrombosis prophylaxis with a predefined intermediate-dose LMWH compared with placebo or no treatment in patients at risk of venous thromboembolism (VTE). We performed a systematic review with meta-analyses and trial sequential analyses (TSA) following The Cochrane Handbook for Systematic Reviews of Interventions . Medline, Cochrane CENTRAL, Web of Science, and Embase were searched up to December 2018. Trials were evaluated for risk of bias and quality of evidence was assessed following the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Seventy randomized trials with 34,046 patients were included. Eighteen (26%) had overall low risk of bias. There was a small statistically significant effect of LMWH on all-cause mortality (risk ratio [RR]: 0.96; TSA-adjusted confidence interval [TSA-adjusted CI]: 0.94-0.98) which disappeared in sensitivity analyses excluding ambulatory cancer patients (RR: 0.99; TSA-adjusted CI: 0.84-1.16). There was moderate-quality evidence for a statistically significant beneficial effect on symptomatic VTE (odds ratio [OR]: 0.59; TSA-adjusted CI: 0.53-0.67; number needed to treat [NNT]: 76; 95% CI: 60-106) and a statistically significant harmful effect on major bleeding (Peto OR: 1.66; TSA-adjusted CI: 1.31-2.10; number needed to harm [NNH]: 212; 95% CI: 142-393). There were no significant intervention effects on serious adverse events. The use of intermediate-dose LMWH for thrombosis prophylaxis compared with placebo or no treatment was associated with a small statistically significant reduction of all-cause mortality that disappeared in sensitivity analyses excluding trials that evaluated LMWH for anticancer treatment. Intermediate-dose LMWH provides benefits in terms of VTE prevention while it increases major bleeding.

Original languageEnglish
Pages (from-to)810-824
Number of pages15
JournalSeminars in thrombosis and hemostasis
Volume45
Issue number8
Publication statusPublished - Nov-2019

    Keywords

  • low-molecular-weight heparin, LMWH, thrombosis, systematic review, meta-analysis, DEEP-VEIN THROMBOSIS, RANDOMIZED CONTROLLED-TRIAL, PLACEBO-CONTROLLED TRIAL, TOTAL HIP-REPLACEMENT, CELL LUNG-CANCER, PHASE-III TRIAL, VENOUS THROMBOEMBOLISM, DOUBLE-BLIND, COMPRESSION STOCKINGS, DALTEPARIN THROMBOPROPHYLAXIS

View graph of relations

ID: 103413196